We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
Other uncategorised cookies are those that are being analysed and have not been classified into a category as yet.

Relfydessâ„¢ â–¼* (RelabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARLâ„¢ Technology, developed and manufactured by Galderma.
.jpg)

Approved for temporary improvement in the appearance of glabellar and lateral canthal lines in adults under 65.

The first liquid neuromodulator in Europe, approved for temporary improvement in the appearance of moderate to severe glabellar lines seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.

Prescribing Information for Azzalure - UK
Prescribing Information for Alluzience - UK
Prescribing Information for Relfydess - UK
UKI-ALA-2500015 March 2025
Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Galderma (UK) Ltd. Email: medinfo.uk@galderma.com Tel: +44 (0)300 3035674
*We provide Galderma (U.K.) Limited with certain information on who has purchased their products through this website for consumer service/support and safety purposes. A copy of Galderma’s Privacy Notice explaining how your data will be collected, used, and disclosed by Galderma can be found here.